Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 131, Issue 20
May 17 2018
Issue Cover

Table of Contents

BLOOD COMMENTARIES

Red Cells, Iron, and Erythropoiesis
Function and dysfunction
Narla Mohandas
View Articletitled, Function and dysfunction
Hematopoiesis and Stem Cells
Ezh2 spares KitL from the cutter
Eric M. Pietras
View Articletitled, Ezh2 spares KitL from the cutter
Lymphoid Neoplasia
TKI resistance in Ph-like ALL
Kathryn G. Roberts
View Articletitled, TKI resistance in Ph-like ALL

PLENARY PAPER

Red Cells, Iron, and Erythropoiesis
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
Clinical Trials & Observations
Rachael F. Grace,Paola Bianchi,Eduard J. van Beers,Stefan W. Eber,Bertil Glader,Hassan M. Yaish,Jenny M. Despotovic,Jennifer A. Rothman,Mukta Sharma,Melissa M. McNaull,Elisa Fermo,Kimberly Lezon-Geyda,D. Holmes Morton,Ellis J. Neufeld,Satheesh Chonat,Nina Kollmar,Christine M. Knoll,Kevin Kuo,Janet L. Kwiatkowski,Dagmar Pospíšilová,Yves D. Pastore,Alexis A. Thompson,Peter E. Newburger,Yaddanapudi Ravindranath,Winfred C. Wang,Marcin W. Wlodarski,Heng Wang,Susanne Holzhauer,Vicky R. Breakey,Joachim Kunz,Sujit Sheth,Melissa J. Rose,Heather A. Bradeen,Nolan Neu,Dongjing Guo,Hasan Al-Sayegh,Wendy B. London,Patrick G. Gallagher,Alberto Zanella,Wilma Barcellini
View Articletitled, Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
Supplemental data

PERSPECTIVE

Biomarkers for posttransplantation outcomes
Clinical Trials & Observations
Sophie Paczesny
View Articletitled, Biomarkers for posttransplantation outcomes

REVIEW ARTICLE

Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia
Richard S. Blumberg,David Lillicrap,the IgG Fc Immune Tolerance Group
View Articletitled, Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia

HOW I TREAT

How I treat the postthrombotic syndrome
Anat Rabinovich,Susan R. Kahn
View Articletitled, How I treat the postthrombotic syndrome

HEMATOPOIESIS AND STEM CELLS

Cell-extrinsic hematopoietic impact of Ezh2 inactivation in fetal liver endothelial cells
Wen Hao Neo,Christopher A. G. Booth,Emanuele Azzoni,Lijun Chi,Paul Delgado-Olguín,Marella F. T. R. de Bruijn,Sten Eirik W. Jacobsen,Adam J. Mead
View Articletitled, Cell-extrinsic hematopoietic impact of Ezh2 inactivation in fetal liver endothelial cells
Supplemental data

LYMPHOID NEOPLASIA

The tumor suppressive TGF-β/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma
Anna Stelling,Hind Hashwah,Katrin Bertram,Markus G. Manz,Alexandar Tzankov,Anne Müller
View Articletitled, The tumor suppressive TGF-β/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma
Supplemental data
SOX11 augments BCR signaling to drive MCL-like tumor development
Pei-Yu Kuo,Shashidhar S. Jatiani,Adeeb H. Rahman,Donna Edwards,Zewei Jiang,Katya Ahr,Deepak Perumal,Violetta V. Leshchenko,Joshua Brody,Rita Shaknovich,B. Hilda Ye,Samir Parekh
View Articletitled, SOX11 augments BCR signaling to drive MCL-like tumor development
Supplemental data
PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia
CME Brief Report
Yingchi Zhang,Yufeng Gao,Hui Zhang,Jingliao Zhang,Fuhong He,Aleš Hnízda,Maoxiang Qian,Xiaoming Liu,Yoshihiro Gocho,Ching-Hon Pui,Tao Cheng,Qianfei Wang,Jun J. Yang,Xiaofan Zhu,Xin Liu
View Articletitled, <em>PDGFRB</em> mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia
Supplemental data

LETTERS TO BLOOD

Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
Ayush Sharma,Naoki Oishi,Rebecca L. Boddicker,Guangzhen Hu,Hailey K. Benson,Rhett P. Ketterling,Patricia T. Greipp,Darlene L. Knutson,Sara M. Kloft-Nelson,Rong He,Bruce W. Eckloff,Jin Jen,Asha A. Nair,Jaime I. Davila,Surendra Dasari,Konstantinos N. Lazaridis,N. Nora Bennani,Tsung-Teh Wu,Grzegorz S. Nowakowski,Joseph A. Murray,Andrew L. Feldman
View Articletitled, Recurrent <em>STAT3-JAK2</em> fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis
Genki Yamato,Norio Shiba,Kenichi Yoshida,Yusuke Hara,Yuichi Shiraishi,Kentaro Ohki,Jun Okubo,Myoung-ja Park,Manabu Sotomatsu,Hirokazu Arakawa,Nobutaka Kiyokawa,Daisuke Tomizawa,Souichi Adachi,Takashi Taga,Keizo Horibe,Satoru Miyano,Seishi Ogawa,Yasuhide Hayashi
View Articletitled, <em>RUNX1</em> mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis
Supplemental data

BLOOD WORK

25-Hydroxyvitamin D3-1α-hydroxylase– and multiple cytokine–producing diffuse large B-cell lymphoma
Shoko Nakayama,Mitsuhiro Matsuda
View Articletitled, 25-Hydroxyvitamin D<sub>3</sub>-1α-hydroxylase– and multiple cytokine–producing diffuse large B-cell lymphoma

ERRATA

Pallasch CP, Schulz A, Kutsch N, et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood. 2008;112(10):4213-4219.
View Articletitled, Pallasch CP, Schulz A, Kutsch N, et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. <em>Blood.</em> 2008;112(10):4213-4219.
Kruse-Jarres R, Johnsen JM. How I treat type 2B von Willebrand disease. Blood. 2018;131(12):1292-1300.
View Articletitled, Kruse-Jarres R, Johnsen JM. How I treat type 2B von Willebrand disease. <em>Blood</em>. 2018;131(12):1292-1300.

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

A novel PDGFRB mutation in TKI-resistant Ph-like ALL
CME
View Articletitled, A novel <em>PDGFRB</em> mutation in TKI-resistant Ph-like ALL
All Issues

Advertisement

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy
NGS-based stratification refines the risk stratification in T-ALL and identifies a Very High-Risk subgroup of patients
Foxo1 is an iron-responsive transcriptional factor regulating systemic iron homeostasis
How I Treat Low-risk Polycythemia Vera Patients who Require Cytoreduction
How I manage major hemorrhage

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement